Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
The data is delayed by 15 minutes.
CASI is in the long-term up 220% in 6 years.
Description: CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops therapeutics to treat cancer and other diseases primarily in the United States and China. The company?s lead drug candidate includes ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer, which has completed Phase I studies in patients with advanced solid tumors, multiple myeloma, and leukemia, as well as it is completing data for a multi-center Phase II study in patients with platinum resistant ovarian cancer. Its other product candidates in development include 2-methoxyestrdiol, an orally active compound for autoimmune diseases; and MKC-1, an orally-active cell cycle inhibitor that has completed Phase II clinical trials for cancer treatment. The company name was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.
|Shares Outstanding||EPS||-0.17||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E||-5.41|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-260.69%||ROE||1454.22%||ROI|
|Current Ratio||3.84||Quick Ratio||Long Term Debt/Equity||Debt Ratio||-1.41|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||Cash From Investing Activities||Cash From Operating Activities||-1.21 M||Gross Profit||20 K|
|Net Profit||-1.8 M||Operating Profit||-1.77 M||Total Assets||10.19 M||Total Current Assets||9.91 M|
|Total Current Liabilities||2.58 M||Total Debt||1.41 M||Total Liabilities||12.01 M||Total Revenue||20 K|
|High 52 week||8.23||Low 52 week||2.77||Last close||3.39||Last change||0.3%|
|RSI||24.77||Average true range||0.23||Beta||0.8||Volume||47.53 K|
|Simple moving average 20 days||-6.68%||Simple moving average 50 days||-13.64%||Simple moving average 200 days||-38.88%|
|Performance Week||0.89%||Performance Month||-16.71%||Performance Quart||-2.59%||Performance Half||-53.75%|
|Performance Year||-15.25%||Performance Year-to-date||-15.67%||Volatility daily||2.65%||Volatility weekly||5.93%|
|Volatility monthly||12.15%||Volatility yearly||42.1%||Relative Volume||117.8%||Average Volume||352.03 K|
|New High||New Low|
2020-06-02 07:00:00 | CASI Pharmaceuticals To Present At The Jefferies 2020 Healthcare Conference
2020-05-31 17:38:21 | Do Hedge Funds Love CASI Pharmaceuticals Inc CASI?
2020-05-11 07:00:00 | CASI Pharmaceuticals Announces First Quarter 2020 Financial Results
2020-05-08 09:05:00 | CASI: A Change in Strategy
2020-04-07 07:00:00 | CASI Pharmaceuticals To Present at 2020 Solebury Trout Virtual Investor Conference
2020-03-31 07:05:50 | CASI Pharmaceuticals, Inc. NASDAQ:CASI Analysts Just Slashed This Year's Estimates
2020-03-16 07:00:00 | CASI Pharmaceuticals Announces Full Year 2019 Financial Results
2020-03-02 06:03:17 | Did Changing Sentiment Drive CASI Pharmaceuticals's NASDAQ:CASI Share Price Down By 47%?
2020-02-07 10:49:03 | Ligand LGND Q4 Earnings & Revenues Top Estimates, Stock Up
2020-01-26 08:33:24 | What You Must Know About CASI Pharmaceuticals, Inc.'s NASDAQ:CASI Beta Value
2019-12-20 05:27:00 | Have Insiders Been Buying CASI Pharmaceuticals, Inc. NASDAQ:CASI Shares?
2019-11-14 05:17:47 | CASI Pharmaceuticals, Inc.'s NASDAQ:CASI Path To Profitability
2019-11-12 07:00:00 | CASI Pharmaceuticals Announces Third Quarter 2019 Financial Results
2019-11-06 09:33:02 | Ligand's LGND Q3 Earnings Miss Estimates, EPS View Down
2019-09-19 07:00:00 | CASI Pharmaceuticals Announces The Promotion Of Larry Zhang To President
2019-09-16 06:00:00 | China NMPA Accepts Clinical Trial Application For CASI's CD19 CAR-T-Product
2019-08-20 19:15:15 | Casi Pharmaceuticals Inc CASI CEO Wei-wu He Bought $64,000 of Shares
2019-08-19 12:22:11 | What Kind Of Shareholders Own CASI Pharmaceuticals, Inc. NASDAQ:CASI?
2019-08-16 10:20:00 | CASI: CASI launches Evomela - first commercial product
2019-08-15 19:15:09 | Casi Pharmaceuticals Inc CASI CEO Wei-wu He Bought $507,200 of Shares
2019-08-12 15:03:45 | Rockville biopharma to sell first product on market in 28 years — but not in the U.S.
2019-08-12 07:00:00 | CASI Pharmaceuticals Announces Launch of EVOMELA® melphalan for injection in China
2019-07-31 10:44:02 | Ligand LGND Stock Down Despite Q2 Earnings & Sales Beat
2019-06-17 07:00:00 | CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
2019-06-03 07:00:00 | CASI Pharmaceuticals To Present At The 2019 BIO International Convention
2019-05-20 09:45:00 | CASI: Making headway towards commercialization
2019-05-15 07:00:00 | CASI Pharmaceuticals Announces First Quarter 2019 Financial and Business Results
2019-05-13 10:00:00 | CASI: Initiating coverage – Leveraging pharmaceutical opportunities in China and beyond
2019-05-03 08:42:12 | Ligand LGND Q1 Earnings & Sales Fall Y/Y, Stock Down
2019-02-26 08:14:52 | When Will CASI Pharmaceuticals, Inc. NASDAQ:CASI Turn A Profit?
2019-02-20 08:15:00 | Report: Developing Opportunities within Pure Storage, Flowers Foods, Cognex, CASI Pharmaceuticals, Ellie Mae, and Douglas Emmett — Future Expectations, Projections Moving into 2019
2019-02-06 07:00:00 | CASI Pharmaceuticals to Present at the BIO CEO & Investor Conference
2018-12-28 11:45:00 | These 4 Healthcare Stocks Are Heating Up